The allegations against Sandoz centered on claims that the company engaged in a conspiracy with competitors to fix prices, rig bids, and allocate markets for certain generic drugs. These practices, if proven, would violate US antitrust laws designed to protect consumers from unfair business practice

The settlement underscores the growing scrutiny of pharmaceutical pricing practices and their impact on patients and healthcare systems. Generic drugs, which account for nearly 90% of prescriptions filled in the US, are supposed to provide affordable alternatives to brand name medications. However,

While the Sandoz settlement resolves one chapter in the legal battle over generic drug pricing, the broader investigation into the industry remains ongoing. Several other pharmaceutical companies are still facing lawsuits or regulatory scrutiny over similar allegations. State attorneys general have

Sandoz to pay $478.5 million in US price fixing settlement

Sandoz, the generics division of Novartis, has agreed to pay $478.5 million to settle allegations of conspiring to artificially inflate and manipulate drug prices in the US. The settlement resolves a years long legal battle with multiple states, which accused the company of engaging in anti competitive practices that drove up healthcare costs. The case highlights ongoing scrutiny of pharmaceutical pricing strategies and their impact on patients and healthcare systems.

Sandoz, the generics arm of Swiss pharmaceutical giant Novartis, has agreed to pay $478.5 million to settle allegations of price fixing in a long running legal dispute with multiple US states. The settlement, announced on Tuesday, resolves claims that the company conspired to artificially inflate prices for generic drugs, a practice that critics argue has contributed to rising healthcare costs across the country.

The agreement follows a multi year investigation led by a coalition of state attorneys general, who accused Sandoz and other pharmaceutical companies of colluding to suppress competition in the generics market. While Sandoz did not admit wrongdoing, the settlement marks one of the largest financial penalties in a case involving allegations of anti competitive behavior in the pharmaceutical industry.